GoodRx (NASDAQ:GDRX) Releases Quarterly Earnings Results, Hits Expectations

GoodRx (NASDAQ:GDRX) released its quarterly earnings data on Wednesday. The company reported $0.07 EPS for the quarter, meeting the consensus estimate of $0.07, FiscalAI reports. GoodRx had a return on equity of 9.31% and a net margin of 3.82%.The firm had revenue of $194.01 million during the quarter, compared to the consensus estimate of $185.12 million. During the same quarter in the previous year, the company posted $0.09 earnings per share. The company’s quarterly revenue was down 4.4% on a year-over-year basis.

GoodRx Trading Up 0.4%

Shares of NASDAQ:GDRX traded up $0.01 during trading on Wednesday, hitting $2.57. The company had a trading volume of 2,005,226 shares, compared to its average volume of 1,447,083. The stock has a market cap of $880.40 million, a price-to-earnings ratio of 28.56, a price-to-earnings-growth ratio of 1.77 and a beta of 1.54. GoodRx has a one year low of $1.77 and a one year high of $5.81. The company has a fifty day simple moving average of $2.20 and a two-hundred day simple moving average of $2.59. The company has a debt-to-equity ratio of 0.78, a current ratio of 2.61 and a quick ratio of 2.61.

Analyst Ratings Changes

GDRX has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. restated a “neutral” rating on shares of GoodRx in a research note on Friday, February 27th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of GoodRx in a research report on Friday, April 10th. Leerink Partners reissued an “outperform” rating and set a $3.00 price objective on shares of GoodRx in a report on Thursday, February 26th. Mizuho dropped their price objective on GoodRx from $4.00 to $3.00 and set a “neutral” rating on the stock in a report on Friday, February 27th. Finally, Citigroup lowered their price target on GoodRx from $4.50 to $3.50 and set a “buy” rating on the stock in a report on Tuesday, March 3rd. Five equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $3.85.

Institutional Investors Weigh In On GoodRx

A number of institutional investors and hedge funds have recently modified their holdings of GDRX. Lazard Asset Management LLC grew its holdings in GoodRx by 43.6% during the 2nd quarter. Lazard Asset Management LLC now owns 17,142 shares of the company’s stock worth $85,000 after acquiring an additional 5,201 shares in the last quarter. Brevan Howard Capital Management LP increased its holdings in shares of GoodRx by 7.7% in the 3rd quarter. Brevan Howard Capital Management LP now owns 95,483 shares of the company’s stock valued at $404,000 after acquiring an additional 6,842 shares during the period. Tower Research Capital LLC TRC increased its holdings in shares of GoodRx by 202.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 11,327 shares of the company’s stock valued at $56,000 after acquiring an additional 7,580 shares during the period. Quarry LP purchased a new position in shares of GoodRx in the 3rd quarter valued at $33,000. Finally, Cetera Investment Advisers purchased a new position in shares of GoodRx in the 2nd quarter valued at $50,000. 63.77% of the stock is owned by institutional investors.

GoodRx Company Profile

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.